Workshop C: Antigen-Specific Targeting of Tumours Across MHC Barriers

Time: 3:00 pm
day: Workshop - Track A - Evening


  • Looking beyond peptide antigens in tumour therapy
  • The advantages of targeting oligomorphic antigen-presenting molecules
  • The advantages of adoptive cell therapies based on MR1- restricted TCRs specific for tumour-associated metabolites, and CD1c-restricted TCRs specific for a leukaemia-associated lipid antigen